- Home
- BAH vs ROIV Comparison
BAH vs ROIV Comparison
Compare BAH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAH
- ROIV
- Stock Information
- Founded
- BAH 1914
- ROIV 2014
- Country
- BAH United States
- ROIV United Kingdom
- Employees
- BAH N/A
- ROIV N/A
- Industry
- BAH Professional Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- BAH Consumer Discretionary
- ROIV Health Care
- Exchange
- BAH Nasdaq
- ROIV Nasdaq
- Market Cap
- BAH 12.0B
- ROIV 14.0B
- IPO Year
- BAH 2010
- ROIV N/A
- Fundamental
- Price
- BAH $80.53
- ROIV $20.23
- Analyst Decision
- BAH Hold
- ROIV Strong Buy
- Analyst Count
- BAH 10
- ROIV 8
- Target Price
- BAH $111.33
- ROIV $21.19
- AVG Volume (30 Days)
- BAH 2.5M
- ROIV 8.7M
- Earning Date
- BAH 10-24-2025
- ROIV 11-10-2025
- Dividend Yield
- BAH 2.75%
- ROIV N/A
- EPS Growth
- BAH 3.12
- ROIV N/A
- EPS
- BAH 6.54
- ROIV N/A
- Revenue
- BAH $11,706,000,000.00
- ROIV $20,329,000.00
- Revenue This Year
- BAH N/A
- ROIV N/A
- Revenue Next Year
- BAH $2.72
- ROIV $320.50
- P/E Ratio
- BAH $12.35
- ROIV N/A
- Revenue Growth
- BAH 2.42
- ROIV N/A
- 52 Week Low
- BAH $79.23
- ROIV $8.73
- 52 Week High
- BAH $151.04
- ROIV $21.35
- Technical
- Relative Strength Index (RSI)
- BAH 29.71
- ROIV 61.82
- Support Level
- BAH $85.03
- ROIV $20.07
- Resistance Level
- BAH $88.20
- ROIV $20.99
- Average True Range (ATR)
- BAH 2.11
- ROIV 0.77
- MACD
- BAH -0.08
- ROIV -0.21
- Stochastic Oscillator
- BAH 12.94
- ROIV 44.31
About BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.